These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 14872558)

  • 21. Model-independent definition of the initial volume of distribution of drugs in the body.
    Piotrovskii VK
    Int J Clin Pharmacol Ther Toxicol; 1986 Aug; 24(8):403-7. PubMed ID: 3759276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
    De Buck SS; Mackie CE
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):865-78. PubMed ID: 18028030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Target-mediated drug disposition and dynamics.
    Mager DE
    Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The prediction of enantiomeric differences in the pharmacokinetic parameters of drugs by using a physiological perfusion model].
    Piotrovskiĭ VK; Shvachko EV; Trnovec T
    Eksp Klin Farmakol; 1994; 57(5):37-40. PubMed ID: 7696904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human.
    Lombardo F; Obach RS; Dicapua FM; Bakken GA; Lu J; Potter DM; Gao F; Miller MD; Zhang Y
    J Med Chem; 2006 Apr; 49(7):2262-7. PubMed ID: 16570922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. QSPR models for the prediction of apparent volume of distribution.
    Ghafourian T; Barzegar-Jalali M; Dastmalchi S; Khavari-Khorasani T; Hakimiha N; Nokhodchi A
    Int J Pharm; 2006 Aug; 319(1-2):82-97. PubMed ID: 16698204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of cadmium in ewes: a preliminary study.
    Han M; Joseph-Enriquez B; Houpert P; Joubert C; Milhaud G
    Vet Hum Toxicol; 1994 Jun; 36(3):185-8. PubMed ID: 8066960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the stochastic modeling of tracer kinetics.
    Matis JH; Tolley HD
    Fed Proc; 1980 Jan; 39(1):104-9. PubMed ID: 7351238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the determination of the time delay in reaching the steady state drug concentration in the organ compared to plasma.
    Berezhkovskiy LM
    J Pharm Sci; 2007 Dec; 96(12):3432-43. PubMed ID: 17628491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model.
    Sobol E; Bialer M
    Biopharm Drug Dispos; 2004 May; 25(4):157-62. PubMed ID: 15108218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Some considerations on the estimation of steady state apparent volume of distribution and the relationships between volume terms.
    Collier PS
    J Pharmacokinet Biopharm; 1983 Feb; 11(1):93-105. PubMed ID: 6875813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of a simulated annealing algorithm to fit compartmental models with an application to fractal pharmacokinetics.
    Marsh RE; Riauka TA; McQuarrie SA
    J Pharm Pharm Sci; 2007; 10(2):168-79. PubMed ID: 17706176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A preliminary pharmacokinetic evaluation of the antimetastatic immunomodulator swainsonine: clinical and toxic implications.
    Bowen D; Adir J; White SL; Bowen CD; Matsumoto K; Olden K
    Anticancer Res; 1993; 13(4):841-4. PubMed ID: 8352552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of the volume of distribution from in vitro data and use for estimating the absolute extent of absorption.
    Ritschel WA; Hammer GV
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):298-316. PubMed ID: 7429676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of human pharmacokinetics--evaluation of methods for prediction of volume of distribution.
    Fagerholm U
    J Pharm Pharmacol; 2007 Sep; 59(9):1181-90. PubMed ID: 17883888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The physiological significance of the apparent volume of distribution, Vdarea or Vd beta, in pharmacokinetic studies.
    Chiou WL
    Res Commun Chem Pathol Pharmacol; 1981 Sep; 33(3):499-508. PubMed ID: 7330454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative structure-pharmacokinetic relationship modelling: apparent volume of distribution.
    Ghafourian T; Barzegar-Jalali M; Hakimiha N; Cronin MT
    J Pharm Pharmacol; 2004 Mar; 56(3):339-50. PubMed ID: 15025859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies.
    Cheung BW; Cartier LL; Russlie HQ; Sawchuk RJ
    Fundam Clin Pharmacol; 2005 Jun; 19(3):347-54. PubMed ID: 15910659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.